Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises

  • Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart
  • Over 400 million people worldwide have diabetes and the amount of insulin required to treat type 2 diabetes alone is expected to increase by more than 20% from 2018 to 2030[1],[2]
  • Sandoz continues to strategically expand their biosimilars portfolio, with eight marketed biosimilars and a robust pipeline, showing ongoing commitment to accessible innovation

…

/by